Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics has announced the publication of breakthrough research showing that increased serum uric acid and overexpression of xanthine oxidase can accelerate the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Their study, published in the American Journal of Physiology-Renal Physiology, reveals the potential of their proprietary drug, XORLO™, to lower uric acid concentrations and mitigate disease progression. This discovery offers hope for more effective treatments for the over 10 million individuals affected by ADPKD globally.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
